Checkpoint Therapeutics Inc.

1.12+0.0100+0.90%Vol 365.99K1Y Perf -61.86%
Jun 24th, 2022 16:00 DELAYED
BID1.10 ASK1.16
Open1.12 Previous Close1.11
Pre-Market- After-Market1.16
 - -  0.04 3.57%
Target Price
22.50 
Analyst Rating
Strong Buy 1.00
Potential %
1.91K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.35 
Earnings Rating
Neutral
Market Cap101.95M 
Earnings Date
4th Aug 2022
Alpha-0.03 Standard Deviation0.23
Beta1.70 

Today's Price Range

1.101.17

52W Range

0.96004.64

5 Year PE Ratio Range

-5.40-4.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
7.69%
1 Month
-10.40%
3 Months
-37.08%
6 Months
-64.10%
1 Year
-61.86%
3 Years
-68.45%
5 Years
-88.80%
10 Years
-

TickerPriceChg.Chg.%
CKPT1.120.01000.90
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
ProfitabilityValueIndustryS&P 500US Markets
-
-26 613.50
-26 613.50
-38 386.60
-
RevenueValueIndustryS&P 500US Markets
252.00K
0.00
-53.93
-34.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.11-0.20-81.82
Q04 2021-0.14-0.39-178.57
Q03 2021-0.13-0.14-7.69
Q02 2021-0.09-0.12-33.33
Q01 2021-0.13-0.0930.77
Q04 2020-0.08-0.17-112.50
Q03 2020-0.08-0.09-12.50
Q02 2020-0.09-0.090.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.1773.44Positive
9/2022 QR-0.1781.72Positive
12/2022 FY-0.70--
12/2023 FY-0.81--
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.17
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume365.99K
Shares Outstanding91.03K
Shares Float69.90M
Trades Count1.57K
Dollar Volume413.76K
Avg. Volume571.02K
Avg. Weekly Volume569.76K
Avg. Monthly Volume521.14K
Avg. Quarterly Volume622.14K

Checkpoint Therapeutics Inc. (NASDAQ: CKPT) stock closed at 1.12 per share at the end of the most recent trading day (a 0.9% change compared to the prior day closing price) with a volume of 365.99K shares and market capitalization of 101.95M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Checkpoint Therapeutics Inc. CEO is James F. Oliviero.

The one-year performance of Checkpoint Therapeutics Inc. stock is -61.86%, while year-to-date (YTD) performance is -63.99%. CKPT stock has a five-year performance of -88.8%. Its 52-week range is between 0.96 and 4.64, which gives CKPT stock a 52-week price range ratio of 4.35%

Checkpoint Therapeutics Inc. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 4.68, a price-to-sale (PS) ratio of 346.78, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -132.81%, a ROC of -180.31% and a ROE of -187.78%. The company’s profit margin is -%, its EBITDA margin is -26 613.50%, and its revenue ttm is $252.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Checkpoint Therapeutics Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. Checkpoint Therapeutics Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Checkpoint Therapeutics Inc. is Strong Buy (1), with a target price of $22.5, which is +1 908.93% compared to the current price. The earnings rating for Checkpoint Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Checkpoint Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Checkpoint Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.25, ATR14 : 0.11, CCI20 : -44.16, Chaikin Money Flow : -0.24, MACD : -0.08, Money Flow Index : 30.71, ROC : -18.25, RSI : 43.17, STOCH (14,3) : 28.57, STOCH RSI : 1.00, UO : 39.06, Williams %R : -71.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Checkpoint Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

CEO: James F. Oliviero

Telephone: +1 781 652-4500

Address: 2 Gansevoort Street, New York 10014, NY, US

Number of employees: 8

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

66%34%

Bearish Bullish

62%38%

TipRanks News for CKPT

News

Stocktwits